On April 3, 2025, Neurona Therapeutics, a clinical-stage, privately held biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, announced the completion of an upsized and oversubscribed $102 million financing. Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, and Spur Capital Partners all participated in the financing round. Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction.

Proceeds from the financing will be used to advance the company’s wholly owned pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead investigational candidate, NRTX-1001, for drug-resistant mesial temporal lobe epilepsy (MTLE), which is among the most common types of epilepsy.

The Wilson Sonsini team that advised Neurona Therapeutics included Ken Clark, Lance Brady, Jacie Valentine, Jacob Morales, Maya Prasad, Anne Seymour, and Seth Cowell.

For more information, please see Neurona Therapeutics’ press release.